Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints

MT NewswiresNov 18 07:55 ET

Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs

MT Newswires14minutes ago

Eli Lilly's Muvalaplin Shows Positive Phase 2 Results in Reducing Heart Disease Risk Factor

MT Newswires48minutes ago

Makers of Weight-Loss Drugs Want Your Employer to Pay for Them -- WSJ

WSJ05:30 ET

Eli Lilly and Co (LLY.US) has a potential first-in-class oral small molecule that significantly reduces Lp(a) levels in adults at high risk of cardiovascular events.

Ruth Gimeno, Vice President of eli lilly and co Diabetes and Metabolism Research Group, said: "We are pleased to see these promising results and look forward to further exploring the next steps of muvalaplin's development."

Zhitong Finance03:43 ET

Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating

Moomoo News03:36 ET · Ratings